Clinical ink Partners with Teckro

Clinical ink is partnering with Teckro for enhanced site engagement.

Clinical ink and Teckro Partner

, a pioneering leader in eSource and complex site data collection, is delighted to announce its partnership with Teckro, a trailblazer in mobile site engagement solutions. The collaboration combines Clinical ink expertise in Direct Data Capture with Teckro's unique mobile app, driving ease of use for research staff and investigators to significantly improve the clinical trial experience.

Clinical ink has a proven track record of managing complex site data collection. The company has prioritized its study solutions to deliver faster time to market, greater ease of use, and better patient experience. Teckro supports informed decisions at the point of care with an intuitive, native mobile app loved by investigators around the world. Together, Clinical ink and Teckro will propel a new era of engagement and usability for site partners.

Expected to be available to site partners globally, the collaboration yields immediate benefits including:

Immediate Execution of Inclusion/Exclusion Review and eConsent Facilitation


Accelerate the process of obtaining electronic consent, reduce administrative burden, and expedite trial enrollment


Eliminate the site burden of managing dozens of passwords to different study sponsor portals

Decentralized Experience for Engaging with Study Experts


Provide immediate answers at the point of care for investigators and site staff

Interconnected Digital Protocol and Seamless Transition to Data Collection


Eliminate the risk of the wrong protocol version being used by sites and streamline data capture

Streamlined Communication for Enhanced Site-Sponsor Collaboration


Open new opportunities for sponsors to proactively communicate with sites and create a direct feedback loop

"We are partnering with Teckro to bring about a paradigm shift in site user engagement and ease of use in clinical trials," says Jonathan Goldman, MD, CEO at Clinical ink. "Combining our expertise in complex site data collection with Teckro's decision support app sets us up to improve site partners’ user experience, compliance, and study timelines."

"By collaborating with Clinical ink for complex site data collection, we are shaping a new era of simplicity and efficiency in clinical trials,” adds Gary Hughes, Co-Founder and CEO at Teckro. “We can further empower investigators and research staff to navigate study answers seamlessly, streamline data capture, and facilitate enhanced collaboration between sites and sponsors."

Teckro is partnering with Clinical ink, a pioneering leader in eSource and complex site data collection.

Clinical ink and Teckro Partner to Enhance Site User Engagement

Teckro Joins SCRS Oncology Advisory Board

Teckro will serve on the SCRS Oncology Advisory Board with a role in its Oncology Program.

SCRS Welcomes Teckro as Oncology Spirit Partner

The Society for Clinical Research Sites (SCRS) is pleased to welcome Teckro as an Oncology Spirit Partner. SCRS Oncology Spirit Partners serve on the SCRS Oncology Advisory Board with leadership roles in its Oncology Program and strategic working groups.

Through this partnership, Teckro will be actively involved in the SCRS Oncology Program and the Global Oncology Site Solutions Summit held annually in Austin, Texas. The Oncology Summit brings research sites, sponsors, CROs, and solution providers together to learn and communicate solutions for more efficient and accessible oncology research.

"As the Teckro representative to the SCRS Oncology Program, my goal is to leverage my clinical trial experience at leading companies such as GSK and Novartis so that together we find ways to simplify oncology trials for everybody working on them and improve the patient experience," said Jennifer Weinberg, Teckro director of oncology strategy.

"With oncology research becoming increasingly more complex and demanding for sites and their patients, strategic industry alliances are working to drive solutions forward quickly. SCRS commends Teckro for their commitment to the SCRS Oncology Spirit Partnership and supporting oncology sites around the world," added Marcus Maleck, SCRS director of global business partnerships.

How the SCRS Oncology program and Global Oncology Site Solutions Summit enables research

Teckro is an Oncology Spirit Partner

About The Society for Clinical Research Sites

Founded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise.

The Society for Clinical Research Sites welcomes Teckro as an SCRS Oncology Advisory Board partner with leadership roles in its Oncology Program and strategic working groups.

Teckro Partners with One Tree Planted

Teckro teams up with reforestation non-profit One Tree Planted.

Teckro Announces Partnership with Non-profit “One Tree Planted”

– Teckro, creator of the only digitally interconnected clinical trial software solution for real-time decision-making at the point of patient care, today announced a partnership with One Tree Planted to support native reforestation in Ireland. Teckro will plant trees quarterly to celebrate new clinical research sites and studies live on the Teckro platform.

“Working with One Tree Planted aligns with Teckro’s ethos of making an impact in the world,” said Gary Hughes, co-founder and chief executive officer. “Digitally interconnected clinical trials are good for the environment with less paper and a reduced need for in-person monitoring visits. This partnership enables us to plant trees in recognition of the sustainable gains achieved with our platform.”

Planting trees is one of the best ways to combat the damaging effects of climate change. Trees help clean the air we breathe, filter the water we drink, and provide habitat to more than 80% of the world’s terrestrial biodiversity. Furthermore, trees are a key ingredient in 25% of all medicines, making reforestation important to the biopharma industry.

“We’re excited to have Teckro’s support for our reforestation project in Ireland,” says Matt Hill, Founder and Chief Environmental Evangelist at One Tree Planted. “We admire their dedication to protecting the environment and raising awareness in the clinical trial industry on the importance of ecosystem restoration.”

The partnership is a simple way for Teckro’s research site users and biopharma customers to contribute to reforestation. Initially, Teckro is committed to support the 200,000-tree project in the Republic of Ireland and Northern Ireland, where trees are planted by local partner organizations and community volunteers. Over time, Teckro’s financial contribution may support other projects in other regions where there is an urgent reforestation need. You can read more about the partnership in a 

One Tree Planted is a 501(c)(3) nonprofit on a mission to make it simple for anyone to help the environment by planting trees. Their projects span the globe and are done in partnership with local communities and knowledgeable experts to create an impact for nature, people, and wildlife. Reforestation helps to rebuild forests after fires and floods, provides jobs for social impact, and restores biodiversity. Many projects have overlapping objectives, creating a combination of benefits that contribute to the UN's Sustainable Development Goals. To learn more, visit 

Teckro announces a tree-planting initiative with One Tree Planted to celebrate environmental benefits of digitally interconnected clinical trials.

Teckro Partners with Reforestation Non-profit “One Tree Planted”

Planting trees celebrates the environmental benefits of digitally interconnected clinical trials

Teckro Joins SCRS as a GIP

SCRS and Teckro are to collaborate in pursuing strategic industry initiatives.

Teckro Joins SCRS as a Global Impact Partner

Society for Clinical Research Sites (SCRS) logo

Today, the Society for Clinical Research Sites (SCRS) announced a Global Impact Partnership with Teckro, a clinical trial hub for consistent collaboration between sites and sponsors. As a Global Impact Partner (GIP), Teckro will align with sponsors, CROs, and service providers dedicated to promoting high-level communication and meaningful partnerships between industry stakeholders and clinical research sites globally. With this collaboration, Teckro will help SCRS set and pursue strategic initiatives and directly work with clinical trial sites and industry peers to address challenges of clinical trials.

“At Teckro we believe that clinical trials, which are often the best possible care for many diseases, must be more accessible to people everywhere. It is the sites and trusted physicians, nurses and other staff who are the heart of clinical research and champion for patients. That’s why we are pleased to partner with SCRS to support this active, vibrant community and to participate in initiatives that will help reduce the burden on sites so they are equipped to manage safer, faster and more efficient clinical trials,” said Gary Hughes, Teckro CEO and co-founder.

Sean Soth, Senior VP of Strategy and Global Business Partnerships for SCRS, commented, “Active communication is a critical factor for site success. Teckro is working to make communication among stakeholders easier, providing sites with relevant guidance when they are with patients. As digital innovation continues to evolve for site personnel, tools and ideas for improved communication will make collaboration easier. SCRS is pleased to recognize Teckro’s involvement in the Global Impact Partner program and looks forward to including their contributions and ideas for sites and industry in 2022 and beyond.”

Learn more about the partnership in the SCRS Talks podcast interview with Silvina Baudino, director of site engagement at Teckro.

Jimmy Bechtel and Silvina Baudino discuss the partnership in the SCRS Talks podcast interview.

Learn more about the SCRS partnership

The Society for Clinical Research Sites and Teckro will collaborate in setting and pursuing strategic industry initiatives with clinical trial sites, sponsors, CROs, and service providers.

Teckro Joins SCRS as Global Impact Partner

Teckro Partners with University of Limerick

Teckro joins the University of Limerick Immersive Software Engineering program.

Teckro Announces Partnership with University of Limerick

Teckro, creator of the only clinical trials solution that facilitates collaboration for real-time decision-making at the point of patient care, today announced a strategic partnership with the University of Limerick. The partnership highlights Teckro’s commitment to world-class technical expertise in Ireland. 

Through its Immersive Software Engineering (ISE) program, the University of Limerick is working with some of the world’s premier technology companies to give students hands-on development experience. Other companies participating in the program include a mix of industry leaders, such as Boston Scientific, Intercom and Stripe.

“Students learn best on the job, with mentoring from both industry and academia. We designed ISE to create a practical, hands-on experience for our students at leading technology companies so they learn by doing,” says Tiziana Margaria, ISE co-director. “We are delighted to have a partner of Teckro’s caliber, not only for their technological expertise, but also for letting our students see first-hand the great work being carried out in the clinical trials space."

While drug development is at the leading edge of scientific innovation, clinical trial processes are often hamstrung by paper-based information systems and slow, unreliable channels of communication. Teckro is leading the way for digital transformation with its clinical trial software platform that provides real-time communication, enables fast, accurate decision-making, and signals potential safety issues sooner, helping the life sciences industry get medicines to market faster.

Students participating in the ISE program with Teckro will have the opportunity to work on technology that is helping to save lives and improve quality of life with modern medicines.

"To deliver the very best technology products to our customers, we need access to the very best development talent, on our doorstep," said Gary Hughes, Teckro CEO and co-founder. "That’s why I am delighted to today announce our partnership with UL to grow the talent pool and culture of technology engineering excellence in Ireland."

 at the University of Limerick will offer a four-year BSc and MSc in Immersive Software Engineering. ISE students will learn in a purpose-built studio at the UL campus in Limerick and on five paid residencies with industry partners. The first cohort of students will begin their studies in September 2022.

Plans to Double R&D Headcount in the Coming Year

Teckro plans to significantly expand its development operations over the coming months, further adding to the technical strength in its Dublin-based R&D hub. The goal is to double the team, bringing the headcount in product and engineering to 100 strong.

“Product leadership is at the very heart of our ambition to transform the clinical trial industry and that means attracting and recruiting the very best people to our development teams,” says Sonia Araujo, Teckro general manager of R&D Products. “We know that the best people are in high demand and so we are eager to support initiatives such as the UL ISE program that will increase the available pool of development talent.”

Recently named as one of the top software startups in Ireland by an independent 

, open Teckro positions include front and back-end developers, DevOps, QA, mobile app developers, product managers and product designers.

Visit the Teckro careers page for open positions

We join the University of Limerick Immersive Software Engineering program to give students hands-on experience at leading global technology innovators.

UL’s Immersive Software Engineering program gives students access to hands-on experience at leading global technology innovators

Teckro Announces Strategic Partnership with the University of Limerick to Expand Ireland’s Technology Talent Pool

Teckro’s New Industry Podcast

We introduce our amazing, brand-new ad-free "Totally Clinical" industry podcast.

Get “Totally Clinical” with Teckro’s Industry Podcast

Teckro, creator of the only clinical trial platform that facilitates collaboration between and among stakeholders, today announced the launch of the 

Totally Clinical: Trial Triumphs & Rad Trends

 podcast. The series provides a medium for diverse stakeholders in the clinical trial ecosystem to engage in conversation; inspiring new ways to design, deliver, and improve participation.

To promote the new podcast series, Teckro worked with award-winning actor John C. McGinley. Known as Dr. Perry Cox in the hit television series 

Totally Clinical episodes cover a variety of topics ranging from field research perspectives and patient experiences, to drug development advances and technology trends. Gary Hughes, Teckro co-founder and CEO, kicks off the series by talking about operating for the greater good and what it means to be a mission-driven company in the 21st Century.

“Teckro is already the hub for effective communication; connecting stakeholders despite the complex, distributed, and often siloed nature of clinical trials,” says Hughes. “Now with the introduction of the Totally Clinical podcast, we are broadening our ambition to engage even more stakeholders in conversations; advancing clinical research and expanding awareness of clinical trials as an option for best possible care.”

Dr. Deborah Zajchowski, scientific director for the non-profit 

, discusses how targeted clinical trials based on tumor biomarkers can 

help increase survival rates for ovarian cancer

Dr. Brendan Buckley, Teckro Chief Medical Officer, explores trends in clinical trials – 

from mega trials to personalized medicine

, presents the research site viewpoint and ways to 

“day in the life” of a clinical research associate

 (CRA) and how the pandemic is driving change for the better.

And Martin Lovell, a prostate cancer survivor, recounts how 

a chance reading of a newspaper article saved his life

“Every initiative that gets people talking is a step forward,” says Dr. Zajchowski, “but the 

 podcast series is also a chance for non-profit organizations to reach other audiences. It allows us to engage in conversations that might accelerate research for treatments and drugs that improve outcomes and survival.”

If you are interested in submitting a topic for consideration, contact us.

Be a Totally Clinical Podcast Guest

Introducing Teckro's Totally Clinical industry podcast as a voice for experts, advocates and stakeholders via engaged discussions... with a special message.

Totally Clinical Industry Podcast Now on Spotify, Apple, Google

The industry podcast is a platform to inspire diverse conversations that advance clinical research and best possible care

Get “Totally Clinical” With Teckro’s New Industry Podcast – Now on Spotify, Apple and Google

Teckro Connect Launched

Teckro's expanded product allows site staff the ability to converse with medical experts.

Unblocking Clinical Research Site Staff with Teckro Connect

Clinical trial software provider Teckro introduces Teckro Connect as the newest feature in its digital engagement solution, giving research site staff direct and immediate access to study experts.

Research staff are blocked without timely answers to questions and clarifications during the conduct of clinical trials. And they can lack confidence in the answers to complex medical questions if they are not directly from expert sources.

The communication challenges facing research site staff surfaced in recent 

 published by the Tufts Center for the Study of Drug Development and Teckro. For example, while study monitors are a main source of protocol information, responses back to site staff take some time. The research also highlights that medical monitors and study teams are rarely resources for research staff.

Connecting Research Sites and Study Experts

Time delays and a lack of trust in the information provided cause unnecessary frustration for research site staff. Teckro addresses this frustration through a combination of mobile self-service access to all study documents with Teckro Search and a secure, dedicated communication channel for research staff to directly query study experts with Teckro Connect.

With Teckro Connect, research staff can ask for clarification or confirm information from the secure Teckro mobile application. The message is received by a dedicated group of medical and scientific experts, giving everyone involved transparency into the response. This leaves no question unanswered and gives staff confidence in the fidelity of the information. It also provides a thread of communication for further clarification, if necessary.

For the first time, sponsors have real-time visibility into site queries and can directly connect study experts in a controlled way with staff conducting the trials. Teckro Connect is compliant with industry regulations, including FDA 21 CFR Part 11. All communication threads are managed to resolution and can be exported for inclusion in the trial master file.

 for more explanation about Teckro Connect and how it helps research staff get study answers they need.

Dr. Brendan Buckley, Chief Medical Officer at Teckro, says, 

We understand and have empathy for how difficult it can be for site staff to conduct clinical trials. We built Teckro because accessing the protocol using old-fashioned methods is inconvenient, inefficient and time-consuming. For this reason, site staff around the world ask for Teckro on their trials.”

Gary Hughes, CEO at Teckro, says, “I am proud of the work we have done to launch Teckro Connect, starting with research to deeply understand the problem. We’re always working on new ideas to make clinical trials stakeholders’ jobs as easy as possible. This is more important than ever, and there is urgent need for simple technology solutions to reform the clinical trials process for better outcomes for staff, sponsors and patients.”

Teckro's expanded digital engagement solution now gives investigative site staff the ability to directly converse with medical experts at the point of care.

Teckro Expands Product Offering with Teckro Connect 

Introducing Teckro Connect to ease pressure on busy staff at research sites

Teckro Expands Product Portfolio to Unblock Clinical Research Site Staff

Teckro Releases Findings on Site Protocol Access

This joint report reveals how site staff access the protocol via "unsophisticated" means.

Tufts CSDD-Teckro: Sites Have Unsophisticated Protocol Access

New industry research finds that investigative site staff most often rely on paper and desktop computers to reference protocol instructions. The research, conducted by the Tufts Center for the Study of Drug Development (CSDD) in collaboration with Teckro, gathered responses from 228 investigative site staff on how and when they interact with the clinical trial protocol. The findings are published in a new 

Tufts CSDD – Teckro 2020 Study on Investigative Site Protocol Administration Referencing Practices

Unsophisticated Approaches Gathering Static Information

One of the major findings was that the majority of respondents (87%) “very” or “somewhat often” refer to paper versions of the protocol. A high percentage (80%) of investigative sites also report relying on direct communication with the study monitor or clinical teams for protocol instructions as well as static PDF versions of the protocol via desktop computers (79%).

Unsurprisingly, smartphones and tablets are rarely used to access online versions of the protocol as navigating PDFs on smaller devices can be difficult. Only four in 10 refer to frequently asked questions via an online portal.

The majority (80%) of respondents report email communication as the primary way they receive protocol amendments. Access to updates via online portals is used by only a small percentage of sites (13%).

“The study results indicate that the majority of investigative sites are using unsophisticated approaches when referring to the protocol to guide clinical trial administration. This is not surprising given the high proportion of sites that are inexperienced, with minimal infrastructure, and — in many cases — involved in clinical trials as a supplemental activity to their clinical practice,” says Ken Getz, Deputy Director of the Tufts CSDD. “As clinical trial activity becomes more virtual and remote, facilitated in part by the pandemic, we expect to see investigative sites using more mobile, flexible technology solutions offering dynamic data updated in real time.”

Separation between the Protocol and Patient

The results also show that the protocol is typically accessed in a distinct area removed from where the patient is seen. Only 7% of respondents store the protocol in the clinic area. Yet, the most referred to sections of the protocol are inclusion/exclusion criteria (97%) and schedule of visits (99%).

With a high percentage of sites turning to study monitors for answers regarding protocol administration, this approach is the most time intensive. Nearly six out of 10 respondents (58%) report that it takes more than 20 minutes to get an answer.

Study Design Complexity Presents Challenges for Staff Looking for Answers

Respondents reveal that the least accessed protocol sections are management of toxicity, data reporting requirements and managing or reporting adverse events. In fact, 42% of respondents rarely or never access the protocol for toxicity management. Such events are typically guided by both study specific and industry standard guidelines that could result in conflicting information in the protocol, which may help to explain why site staff do not directly refer to the protocol in such instances.

“What started with a question turned into a collaborative research project between Teckro and Tufts CSDD. The results point to ways we need to make it easier for research staff to conduct clinical trials,” says Dr. Brendan Buckley, Teckro Chief Medical Officer. “It’s usual for people to do an online search or to ask Siri or Alexa when they have a question. Within an instant, they get access to hundreds, thousands or even millions of answers. Why isn’t it the same with clinical trials?

Study on Investigative Site Protocol Administration Referencing Practices

Tufts CSDD - Teckro 2020 Report

The Digital Paradox: Research Sites and the Clinical Trial Protocol

Companion Analysis and Infographic

Read about Tufts CSDD and Teckro's findings on static paper documents as the primary means of clinical protocol access despite the availability of newer, efficient tech.

Research Finds Investigative Site Staff Access Protocol as Paper 

Clinical trials are largely guided by static versions with staff referring to paper protocols or PDF files on desktop computers

New Industry Research Finds that Investigative Sites Use Unsophisticated Approaches to Access Protocol Instructions, Despite Availability of Newer Technologies 

Teckro Adds New Products Following High Adoption

With 91% of registered users active, Teckro is expanding its suite of clinical trial software.

High-growth clinical trials solution Teckro added two new software products in its mission to transform the industry’s efficiency and make trials more transparent for doctors, researchers and patients.

The company uses machine-learning technology to transform clinical trial protocols from static documents into actionable data for research staff, monitors and sponsors. Intuitive and simple, 91% of registered users are active.

Now researchers responsible for testing new medical treatments on patients around the world can receive up-to-date study information and provide feedback to improve performance with the addition of Teckro Engage and Teckro Survey.

The new functionality will build on the Teckro Search product to accelerate the speed and precision by which clinical research stakeholders can locate and distribute the right information found in current, approved documents, as well as monitor engagement and trial conduct.

Teckro CEO and Co-founder Gary Hughes said: “Teckro brings simplicity to the complexity of clinical trials. The high adoption and extremely positive user feedback are unheard of for typical software companies. We are adding to the value of Teckro with the new products, which we designed to be intuitive and easy to use.”

With more than 12,000 research sites using the software – and steadily rising – Teckro holds a vast amount of valuable insight across clinical studies around the world. That volume of data will help transform what has – until now – been a painstakingly slow clinical research process, into one that is effective for every stakeholder.

Dana Anderson, CCRC at North Georgia Clinical Research has been responsible for coordinating clinical trials for 18 years. She is using Teckro for a current global clinical trial and said it is making it easier to do her job as a site coordinator.

“A research project involves so many stakeholders and so much paperwork. Most of the time it’s very difficult to find exactly what you’re looking for,” Anderson said. “Once I downloaded Teckro to my phone, I realized this is going to make my job much easier. It's very easy to navigate and find what information you need to retrieve from the protocol or the study design. Teckro gives us the resources that we need to make sure our data is clean and accurate. And it's nice that Teckro always will have the current amendment on there, so you know that you're following the correct protocol.”

Teckro Engage gives study administrators a consistent way to communicate important changes, new document versions, or helpful tips to limit protocol deviation. Open rates show message effectiveness.

Teckro Survey is a web-based tool for study teams to quickly design and send short surveys, making it practical to gather feedback from research staff to manage risk and improve study design.

Available through a secure mobile application or a website, Teckro doesn’t require any software installation. As a result, Teckro is operational in a matter of a couple of weeks and requires minimal user training.

Business impact to date is impressive. Teckro’s own data shows that sites using Teckro screen and randomize significantly more patients compared with those without Teckro. Those sites actively searching in Teckro perform much better to meet recruitment timelines, addressing a major barrier to conducting clinical trials.

With 91% of registered active users, Teckro is expanding its suite of clinical trial software to transform efficiency for doctors, researchers and patients.

Teckro Adds New Products Following Sky-High User Adoption 

Revolutionizing the way clinical trials are run

Teckro Adds New Products Following Sky-High User Adoption

Teckro Raises $6 Million Series A Funding

Teckro raises $6m Series A funding from Founders Fund and Enterprise Ireland.

Teckro, a life sciences technology company, has raised $6 million in Series A funding to support further development and expansion of its mobile software solution for clinical trials. The investment was led by San Francisco-based Founders Fund with participation from Enterprise Ireland and private investors. This brings the total amount of funding raised to date to $7.8 million.

Teckro uses information retrieval and machine learning technologies to improve the speed and accuracy of trial conduct. The technology has already been adopted by a number of leading pharmaceutical companies.

CEO Gary Hughes commented: “We set out to make a difference, to make it easier for drug developers, research staff and patients to connect, and to simplify every interaction in the conduct of a clinical trial. The funding will be used to expand our product development team as we continue to digitize clinical research services.”

Hughes added: “Fundamentally, the clinical trial landscape has changed and physicians struggle with the current method of conducting clinical trials. The funding we are announcing today validates our unique approach and the growth potential of the company.”

Teckro was co-founded by Gary Hughes, Jacek Skryzpiec and Nigel Hughes. They were previously co-founders of Firecrest Clinical, which was acquired by ICON Plc in 2011. Teckro is chaired by Peter Gray, former CEO of ICON, who is also Chairman of UDG Healthcare plc and a director of Jazz Pharmaceuticals plc and Aptuit LLC.

Scott Nolan, Partner at Founders Fund, commented: “We’re really impressed by the Teckro team and their vision for clinical research. There’s a clear opportunity in modernizing how clinical trials are run, and Teckro’s mobile-first solution is informed by a first hand understanding of the challenges involved in conducting global clinical trials.”

Founders Fund invests in science and technology companies solving the world’s most difficult problems. The firm and its partners have been early backers of some of the most prominent companies of the past decade, including SpaceX, Palantir, Facebook and Airbnb. Founders Fund pursues a founder-friendly investment strategy that provides maximum support with minimum interference.

Teckro raises $6 million Series A round from Founders Fund, Enterprise Ireland and private investors. Total funding to date is $7.8 million.

Founders Fund Leads Teckro $6m Series A Financing Round 

Financing round led by Founders Fund

Teckro Completes $6 Million Series A Funding

Teckro Announces 45 Dublin Tech Jobs

Teckro announces 45 jobs as part of further investment in digital product development.

Teckro Announces 45 High Tech Dublin Jobs

Teckro, the indigenous Irish firm transforming clinical trials for leading pharmaceutical and emerging biotech companies today officially announced 45 high-end tech jobs for Dublin, representing more than 100% growth in staff here.

The company currently has more than 110 employees with offices in Limerick and the US, but the majority of the new roles will be in the company’s Engineering Excellence Hub in Dublin’s Silicon Docks. The technical jobs will span functions across engineering, data science, design and usability, quality and product management.

The staff expansion follows the recent appointments of Anita Callan as Vice President of Product, most recently from Aer Lingus, and Neil Flanagan as Vice President of Engineering, previously with Munich Re to Teckro’s leadership team.

Speaking at the announcement CEO and Co-Founder Gary Hughes said, “Although technology has revolutionized so many industries, the experience of participating in a clinical trial if you are a doctor, research nurse or patient has not changed in the last two decades. The industry still heavily relies on paper and inefficient processes. At Teckro, we are on a mission to simplify the process and make clinical trials more accessible for everyone involved. We are looking for more talented people, especially in technical roles, to join us and make an impact.”

The company, founded in 2015 by brothers Gary and Nigel Hughes and CTO Jacek Skrzypiec, is currently in scale out mode. This is the second startup founded in Ireland by the Hughes brothers and Skrzypiec, whose previous business, Firecrest Clinical, was sold to Nasdaq-listed clinical research giant ICON in 2011.

Teckro provides solutions to simplify and modernize clinical research for leading pharmaceutical and biotech companies, currently managing more than 100 clinical trials and actively used by more than 11,800 study sites worldwide. Earlier this year the company announced a Series C funding round from major US venture capital firms, including Founders Fund, Bill Maris’ Section 32, Borealis Ventures, Northpond Ventures and Sands Capital Ventures that brought its total funding to $43 million and making it one of the fastest growing venture-backed companies developing product in Ireland.

Minister for Business, Enterprise and Innovation Heather Humphreys welcomed the jobs saying, “It’s great to see an Irish company based in Dublin and Limerick succeed and grow internationally, especially one with a mission that will ultimately benefit patients and healthcare professionals in research to address global health problems. These 45 new tech jobs will play an important role for Teckro to deliver solutions from Ireland that will improve the clinical trial process throughout the world. This is another great example of how our SMEs are investing in new technologies, which is an important element in our Future Jobs Ireland strategy.”

The Dublin-based clinical trials software company Teckro announces 45 high-end jobs at its Engineering Excellence Hub as part of further investment in digital product development.

Teckro Announces 45 High Tech Jobs in Dublin 

Main expansion is in Dublin-based Engineering Excellence Hub as Teckro heavily invests in product development to simplify and modernize clinical research

Teckro Announces 45 High Tech Jobs in Dublin

Teckro Raises $25 Million Series C Funding

Teckro raises Series C funding to accelerate international expansion.

Teckro has raised a fresh round of funding to accelerate its international expansion and product development. The $25 million Series C round was led by Northpond Ventures with participation from Founders Fund, Sands Capital Ventures, Bill Maris’ Section 32 venture fund, and Borealis Ventures. Teckro’s total funding now stands at $43 million.

The company provides technology to improve the speed and accuracy of clinical trials, working with the top pharmaceutical and biotech companies globally. Teckro has grown rapidly since it was founded by brothers Gary and Nigel Hughes and Jacek Skrzypiec in 2015. The founders sold their previous company, Firecrest, to global clinical research giant ICON plc in 2011.

Teckro is used in clinical research sites around the world in all major countries. There has been a 240% increase in the number of clinical trials on Teckro over the past 12 months. The company employs more than 100 staff across its three global bases, including its global headquarters in Limerick, Ireland, its engineering hub in Dublin, Ireland and its US office in Nashville, Tennessee.

Speaking on the funding announcement, CEO and co-founder Gary Hughes said the company will use the Series C round to further the company’s mission to deliver solutions that deliver meaningfully impact and improve processes for all stakeholders involved in clinical trials. “Despite all the talk of digital transformation, the actual experience of participating in a clinical trial if you are a doctor, research nurse or patient has changed little in the last 20 years.

The industry still relies heavily on paper, on working off retrospective data, and there is still an over-reliance on sending CRAs to busy research sites. This approach, together with the plethora of point solutions that get ‘bolted on’, only adds to the complexity and disjointed experience of research sites and patients.

Our vision is to be at the center of all site and patient interactions in a clinical trial. We are building a new digital infrastructure and toolset for clinical research that makes the conduct of trials simpler, more transparent and more inclusive.

Ultimately Teckro is about ensuring that effective drugs are efficiently and effectively moved from the lab to the patient so that lives be saved.”

Michael Rubin, M.D., Ph.D., Founder & CEO of Northpond Ventures commented: “Teckro is building a digital infrastructure that can transform how clinical trials are conducted. We are excited by the team and what they have achieved to date and look forward to supporting them on this important mission.”

Teckro raises an additional $25 million from Northpond Ventures, Founders Fund and Bill Maris’ Section 32 to accelerate international expansion and product development.

Read

Listen

Watch

Company News